Download Sample
Add to CartGlobal Quinine Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product Type;
Quinine Sulphate, Quinine Hydrochloride, Quinine Gluconate , and Quinine BisulphateBy Source;
Cinchona Bark and SyntheticBy Mode Of Administration;
Oral Administration, Intravenous Administration, Intramuscular Administration, and OthersBy Application;
Antimalarial, Antipyretic, and OthersBy End User;
Hospitals, Clinics, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Quinine Market Overview
Quinine Market (USD Million)
Quinine Market was valued at USD 2,110.62 million in the year 2024. The size of this market is expected to increase to USD 3,148.53 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.9%.
Global Quinine Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 5.9 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 5.9 % |
| Market Size (2024) | USD 2,110.62 Million |
| Market Size (2031) | USD 3,148.53 Million |
| Market Concentration | Medium |
| Report Pages | 319 |
Major Players
- Fagron NV
- GlaxoSmithKline plc
- Novartis AG
- Alkaloids Corporation
- Neos Therapeutics, Inc.
- Apotex Inc.
- Sun Pharmaceutical Industries Ltd.
- Taj Pharmaceuticals Limited
- Sandoz International GmbH (Novartis AG subsidiary)
- Alchem International Pvt. Ltd.
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Quinine Market
Fragmented - Highly competitive market without dominant players
The Quinine Market is experiencing consistent growth, primarily driven by its critical role in pharmaceuticals, beverages, and industrial applications. Quinine, a naturally derived alkaloid from the bark of the cinchona tree, remains a vital therapeutic agent for malaria treatment, representing nearly 60% of total quinine consumption. This ongoing demand is supported by the persistent global focus on combating malaria and the need for effective antimalarial therapies.
Diversifying Industrial Applications
Beyond its traditional uses, quinine is also utilized in various industrial processes, including chemical synthesis, dye production, and fluorescence standards. As industries continue to innovate, this share is expected to expand further, supporting long-term market growth.
Focus on Innovation and Product Enhancement
To meet rising demand, many producers are investing in advanced extraction and processing technologies to improve efficiency and product quality. Currently, nearly 40% of quinine manufacturers are focused on enhancing their production capabilities, ensuring a more sustainable and cost-effective supply chain. These innovations are crucial for maintaining product consistency and meeting evolving market expectations.
Growth Prospects and Future Outlook
The quinine market is poised for steady expansion in the coming years, driven by ongoing demand in the healthcare and beverage sectors. Industry estimates suggest an average annual growth rate of 5-7%, underpinned by technological advancements, increasing health awareness, and the continuous development of novel applications for quinine.
Quinine Market Recent Developments
-
In June 2022, Bickford & Sons, a renowned South Australian brand, introduced a new tonic water crafted using natural ingredients, including carbonated water, quinine, and a choice of sugar or natural sweetener. This launch reflects the brand's commitment to quality and the growing demand for premium beverages, appealing to health-conscious consumers seeking authentic, flavorful mixers.
-
In March 2022, Fever-Tree, a leading name in the premium mixers category, expanded its tonic water range in Spain with the launch of Raspberry & Rhubarb Tonic Water. This new variant is crafted using the finest natural quinine sourced from the Congo, combined with Scottish raspberries and English rhubarb, delivering a distinctive, refreshing flavor profile that appeals to discerning consumers.
Quinine Market Segment Analysis
In this report, the Quinine Market has been segmented by Product Type, Source, Mode of Administration, Application and Geography.
Quinine Market, Segmentation by Product Type
The Quinine Market has been segmented by Product Type into Quinine Sulphate, Quinine Hydrochloride, Quinine Gluconate, and Quinine Bisulphate.
Quinine Sulphate
Quinine sulphate remains the most widely used form of quinine in the global market, accounting for approximately 45% of the total market share. This form of quinine is primarily used for the treatment of malaria due to its efficacy in eliminating the malaria parasite from the body. Its long-standing use in medical applications continues to maintain its dominance.
Quinine Hydrochloride
Quinine hydrochloride holds a significant portion of the market at around 30%. It is commonly used in pharmaceutical formulations for treating malaria and as a component in various medications. The drug's effectiveness in treating both acute and chronic malaria cases contributes to its substantial market share.
Quinine Gluconate
Quinine gluconate is gaining traction in the quinine market, contributing to 15% of the total market share. It is primarily utilized in intravenous treatments for severe cases of malaria, particularly in patients who require rapid treatment. Its effectiveness in critical conditions helps maintain its importance within the global market.
Quinine Bisulphate
Quinine bisulphate accounts for approximately 10% of the quinine market. It is typically used in combination therapies for malaria and muscle cramps treatment. Although it holds a smaller share in comparison to other quinine types, its niche use in medical treatments supports its continued presence in the market.
Quinine Market, Segmentation by Source
The Quinine Market has been segmented by Source into Cinchona Bark, and Synthetic.
Cinchona Bark
Cinchona bark remains the dominant source of quinine, representing approximately 60% of the global market. It has been used for centuries as a natural remedy for malaria and continues to be a vital part of quinine production. Its use in the pharmaceutical industry is prevalent due to its high alkaloid content, which is ideal for quinine extraction.
Synthetic
The synthetic quinine market has been growing steadily, now contributing to 40% of the overall market. Synthetic quinine is favored in modern pharmaceutical applications due to its consistency, cost-effectiveness, and availability. With advancements in biotechnology, synthetic quinine has become an increasingly reliable alternative to natural sources.
Quinine Market, Segmentation by Mode of Administration
The Quinine Market has been segmented by Mode of Administration into Oral Administration, Intravenous Administration, Intramuscular Administration and Others.
Oral Administration
Oral administration of quinine remains the most common method, contributing to around 55% of the global market. This form is popular due to its ease of use and convenience for both patients and healthcare providers. The availability of oral quinine formulations, such as tablets and capsules, makes it an accessible treatment option for malaria and other diseases.
Intravenous Administration
Intravenous administration is preferred in cases of severe malaria or when immediate action is required. It holds a market share of approximately 30%. This method allows for rapid absorption of quinine into the bloodstream, providing faster therapeutic effects compared to oral administration.
Intramuscular Administration
Intramuscular administration accounts for about 10% of the quinine market. It is used in situations where intravenous access is not feasible. The method allows for steady drug release, though it is less commonly used than oral or intravenous options.
Quinine Market, Segmentation by Application
The Quinine Market has been segmented by Application into Antimalarial, Antipyretic and Others.
Antimalarial
Quinine is primarily used in the treatment of malaria, contributing to approximately 70% of the market share. It is one of the most effective treatments for severe forms of malaria, especially in regions where Plasmodium falciparum is prevalent. This use remains critical in sub-Saharan Africa, where malaria is endemic.
Antipyretic
Quinine is also utilized as an antipyretic for fever reduction, accounting for about 20% of its global use. The ability of quinine to reduce high fever makes it a popular option for fever management, particularly in areas with malaria outbreaks. Despite its efficacy, its use for fever has decreased with the development of more targeted treatments.
Quinine Market, Segmentation by End User
The Quinine Market has been segmented by End User into Hospitals, Clinics, and Others.
Hospitals
Hospitals dominate the quinine market, accounting for approximately 60% of global demand. Quinine is frequently administered in hospitals for severe cases of malaria, especially in emergency settings. Hospitals are the primary healthcare providers in regions where malaria is endemic, and the use of quinine in these settings remains vital.
Clinics
Clinics account for about 30% of quinine's market share. In outpatient settings, quinine is commonly used for treating mild to moderate malaria cases, often in regions with limited access to more advanced treatment options. Clinics provide essential care for non-emergency patients, driving the demand for quinine.
Quinine Market, Segmentation by Geography
In this report, the Quinine Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Quinine Market Share (%), by Geographical Region, 2024
North America
North America represents a significant portion of the quinine market, accounting for around 15% of the total demand. The use of quinine is primarily for antimalarial purposes, particularly in travelers returning from malaria-endemic regions. The healthcare infrastructure in this region supports quick access to quinine-based treatments, driving market growth.
Europe
Europe contributes about 20% to the quinine market. Quinine is widely used in European countries for treating severe malaria cases among travelers and expatriates. The region also has a strong demand for quinine as part of research into antimalarial therapies and treatments for other conditions like muscle cramps.
Asia Pacific
Asia Pacific holds the largest share of the quinine market, with approximately 40% of global consumption. This region is heavily impacted by malaria, driving high demand for quinine-based treatments. Quinine is often used in rural and remote areas where access to advanced healthcare is limited, playing a key role in malaria eradication efforts.
Middle East and Africa
The Middle East and Africa region together account for around 10% of the quinine market. Quinine is vital in sub-Saharan Africa, where malaria remains a major public
Quinine Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Quinine Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Persistence of Malaria Threat
- Off-Label Use for Nocturnal Leg Cramps
-
Demand in Regions with Drug Resistance - The rising occurrence of drug-resistant malaria strains in regions like Sub-Saharan Africa, Southeast Asia, and South America is significantly increasing the demand for quinine. As commonly prescribed antimalarial treatments lose effectiveness, healthcare providers are turning to quinine as a reliable solution for combating severe and resistant cases. This shift is particularly evident in regions where alternative therapies have shown diminished success rates, making quinine a preferred treatment option.
Quinine continues to hold relevance due to its proven efficacy against Plasmodium falciparum, the deadliest malaria parasite. With resistance to artemisinin-based combination therapies (ACTs) emerging in many high-risk zones, medical institutions and health authorities are reintegrating quinine into treatment protocols. This has led to renewed interest in quinine-based drugs and further investigation into more effective formulations and combinations.
In specific patient groups, such as pregnant women or individuals with certain medical conditions, quinine is often more suitable than newer therapies. It is also widely used in resource-limited and emergency settings, where diagnostics are minimal and healthcare infrastructure is weak. In such scenarios, quinine serves as a first-line defense, particularly during malaria outbreaks in conflict zones and refugee camps, where drug resistance can spread more rapidly.
This growing dependence on quinine has prompted increased activity from pharmaceutical manufacturers and global health suppliers. Organizations focusing on public health and humanitarian aid are ramping up their procurement of quinine-based medications. This surge reinforces quinine’s strategic importance in the global effort to manage and treat drug-resistant malaria, ensuring it remains a critical tool in disease control even as new therapies are developed.
Restraints
- Limited Availability of Cinchona Bark
- Regulatory Hurdles and Safety Concerns
-
Competition from Synthetic Antimalarials - The quinine market is increasingly constrained by the widespread use of synthetic antimalarial drugs. Treatments such as artemisinin-based combination therapies (ACTs) have gained prominence due to their rapid effectiveness, fewer side effects, and greater patient adherence. These modern formulations are now the preferred choice for malaria treatment across most healthcare systems, particularly in public health initiatives supported by global health organizations.
One of the key drawbacks of quinine is its lengthy treatment duration and the higher incidence of adverse effects, including tinnitus, headaches, and gastrointestinal issues. These factors often result in poor compliance, making it less favorable compared to synthetic alternatives that are easier to administer and better tolerated. As a result, many healthcare providers are phasing out quinine in favor of more convenient therapies that offer faster recovery with minimal discomfort.
The market appeal of synthetic antimalarials is also driven by their cost-efficiency and scalability. These drugs can be produced in bulk at lower costs, allowing them to be distributed widely through subsidized healthcare programs and international aid efforts. In many malaria-endemic regions, national treatment policies now prioritize these modern options over quinine, further diminishing its role in mainstream malaria control efforts.
Despite its continued relevance in treating severe malaria cases and drug-resistant infections, quinine is gradually being relegated to a secondary position within the therapeutic landscape. The rise of highly effective synthetic treatments has narrowed its usage, limiting market growth and reducing its prominence in global antimalarial strategies.
Opportunities
- Sustainable Cultivation Practices
- Research for Optimization and Expansion
-
Market Growth in Emerging Economies - The quinine market is gaining momentum due to increased healthcare investments and a high disease burden in emerging economies. Nations across Africa, Southeast Asia, and Latin America are seeing persistent rates of malaria, creating sustained demand for effective antimalarial treatments. As these countries expand their healthcare systems and improve access to essential drugs, quinine continues to play a critical role, especially in treating severe or drug-resistant malaria cases.
Many emerging regions are working closely with global health organizations to combat malaria through targeted public health programs. These partnerships have led to increased funding, improved supply chain infrastructure, and higher procurement of antimalarial drugs like quinine. In areas where advanced synthetic treatments are either too costly or less accessible, quinine remains a cost-effective and reliable solution for widespread treatment.
The rise in domestic pharmaceutical manufacturing in developing countries is contributing to broader quinine availability. By reducing reliance on imports, local production helps lower costs and enhances drug accessibility across remote areas. This shift allows more people in rural and underserved communities to receive effective treatment, particularly where malaria prevalence remains high and healthcare access is limited.
Growing awareness about malaria prevention, along with the rollout of government-subsidized healthcare programs, is encouraging more individuals to seek early treatment. As healthcare coverage expands and more populations are included in national malaria control efforts, the demand for quinine is projected to grow. These developments present a strong opportunity for stakeholders to strengthen their market position in high-burden and high-growth regions.
Quinine Market Competitive Landscape Analysis
Key players in Quinine Market include:
- Fagron NV
- GlaxoSmithKline plc
- Novartis AG
- Alkaloids Corporation
- Neos Therapeutics, Inc.
- Apotex Inc.
- Sun Pharmaceutical Industries Ltd.
- Taj Pharmaceuticals Limited
- Sandoz International GmbH (Novartis AG subsidiary)
- Alchem International Pvt. Ltd.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Source
- Market Snapshot, By Mode of Administration
- Market Snapshot, By Application
-
Market Snapshot, By End User
- Market Snapshot, By Region
- Quinine Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Persistence of Malaria Threat
- Off-Label Use for Nocturnal Leg Cramps
- Demand in Regions with Drug Resistance
- Restraints
- Limited Availability of Cinchona Bark
- Regulatory Hurdles and Safety Concerns
- Competition from Synthetic Antimalarials
- Opportunities
- Sustainable Cultivation Practices
- Research for Optimization and Expansion
- Market Growth in Emerging Economie
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Quinine Market, By Product Type, 2021 - 2031 (USD Million)
- Quinine Sulphate
- Quinine Hydrochloride
- Quinine Gluconate
- Quinine Bisulphate
- Quinine Market, By Source, 2021 - 2031 (USD Million)
- Cinchona Bark
- Synthetic
- Quinine Market, By Mode of Administration, 2021 - 2031 (USD Million)
- Oral Administration
- Intravenous Administration
- Intramuscular Administration
- Others
- Quinine Market, By Application, 2021 - 2031 (USD Million)
- Antimalarial
- Antipyretic
- Others
-
Quinine Market, By End User, 2021 - 2031 (USD Million)
-
Hospitals
-
Clinics
-
Others
-
- Quinine Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Quinine Market, By Product Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Fagron NV
- GlaxoSmithKline plc
- Novartis AG
- Alkaloids Corporation
- Neos Therapeutics Inc.
- Apotex Inc.
- Sun Pharmaceutical Industries Ltd.
- Taj Pharmaceuticals Limited
- Sandoz International GmbH (Novartis AG subsidiary)
- Alchem International Pvt. Ltd.
- Company Profiles
- Analyst Views
- Future Outlook of the Market